Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genetic testing for neonates must be restricted, says EC:

This article was originally published in Clinica

Executive Summary

"Genetic testing can certainly help in the early detection of illnesses, but can never be made compulsory". That is the statement being made by European Research Commissioner Philippe Busquin, who denies stories in the media, which has reported that he has called for genetic testing of all newborn babies in Europe. This issue has come to the fore following a recent presentation of recommendations by a Commission expert group looking at the ethical legal and social implications of genetic testing. This group has proposed that for "rare but serious diseases for which treatment is available, member states should introduce universal neonatal screening". A statement issued by the Commission has confirmed that the group "is not asking the European Commission nor member states to launch any global post-natal genetic screening programme, but to consider screening only for those rare and serious diseases for which treatments already exist". For more details on the findings of the group, see: http://europa.eu.int/comm/research/conferences/2004/ genetic/index-en.htm

You may also be interested in...



Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT059004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel